Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920264 · ClinicalTrials.gov registry record · Phase 1
Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial
A Phase 1 study of This Study Will Evaluate Whether TXA Reduces Pain, sponsored by St. Louis Joint Replacement Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
- 1
- Study location
NCT06920264: Completed Phase 1 study of This Study Will Evaluate Whether TXA Reduces Pain, sponsored by St. Louis Joint Replacement Institute.
NCT06920264 is a Phase 1 study of This Study Will Evaluate Whether TXA Reduces Pain that has completed, run by St. Louis Joint Replacement Institute. The registered enrollment target is 165 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (175% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06920264, a Phase 1 study of This Study Will Evaluate Whether TXA Reduces Pain, has completed, sponsored by St. Louis Joint Replacement Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
To our knowledge, no studies examining the use of TXA after shoulder arthroscopy in an outpatient setting have been published. This study will evaluate whether TXA reduces pain as measured by opioid consumption and a visual analog scale for pain (VAS) for the first 72 hours after surgery. Secondary outcomes will examine whether patients were satisfied overall with their postoperative pain control, whether the time to first opioid use is increased, and whether the surgeon perceives improved surgical visualization in patients who received TXA. We will also examine the number of times pump pressure was increased during the procedure to improve visualization.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Tranexamic acid
Study Locations (1)
Missouri
- SSM Health- DePaul - Bridgeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 1 |
What the finished NCT06920264 record still lists
NCT06920264 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (175% higher).
The record links to 1 condition, with This Study Will Evaluate Whether TXA Reduces Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06920264 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06920264 about?
NCT06920264 is a clinical study titled "Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial". To our knowledge, no studies examining the use of TXA after shoulder arthroscopy in an outpatient setting have been published. This study will evaluate whether TXA reduces pain as measured by opioid consumption and a visual analog scale for pain (VAS) for the first 72 hours after surgery. Secondary ...
What is the current status of trial NCT06920264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2021-07-01. Estimated completion is 2024-09-30.
What conditions does trial NCT06920264 study?
This clinical trial studies the following conditions: This Study Will Evaluate Whether TXA Reduces Pain.
What interventions are being tested in trial NCT06920264?
The interventions under investigation include: placebo (OTHER), Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT06920264?
This trial is sponsored by St. Louis Joint Replacement Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920264 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06920264's enrollment target sits among peer trials
165 332nd of 2000 higher than 1,666 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI